Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2008 May 29;453(7195):667-71.
doi: 10.1038/nature06890. Epub 2008 Apr 30.

Rapid cloning of high-affinity human monoclonal antibodies against influenza virus

Jens Wrammert  1 , Kenneth Smith, Joe Miller, William A Langley, Kenneth Kokko, Christian Larsen, Nai-Ying Zheng, Israel Mays, Lori Garman, Christina Helms, Judith James, Gillian M Air, J Donald Capra, Rafi Ahmed, Patrick C Wilson
Affiliations
Clinical Trial

Rapid cloning of high-affinity human monoclonal antibodies against influenza virus

Jens Wrammert et al. Nature. .

Abstract

Pre-existing neutralizing antibody provides the first line of defence against pathogens in general. For influenza virus, annual vaccinations are given to maintain protective levels of antibody against the currently circulating strains. Here we report that after booster vaccination there was a rapid and robust influenza-specific IgG+ antibody-secreting plasma cell (ASC) response that peaked at approximately day 7 and accounted for up to 6% of peripheral blood B cells. These ASCs could be distinguished from influenza-specific IgG+ memory B cells that peaked 14-21 days after vaccination and averaged 1% of all B cells. Importantly, as much as 80% of ASCs purified at the peak of the response were influenza specific. This ASC response was characterized by a highly restricted B-cell receptor (BCR) repertoire that in some donors was dominated by only a few B-cell clones. This pauci-clonal response, however, showed extensive intraclonal diversification from accumulated somatic mutations. We used the immunoglobulin variable regions isolated from sorted single ASCs to produce over 50 human monoclonal antibodies (mAbs) that bound to the three influenza vaccine strains with high affinity. This strategy demonstrates that we can generate multiple high-affinity mAbs from humans within a month after vaccination. The panel of influenza-virus-specific human mAbs allowed us to address the issue of original antigenic sin (OAS): the phenomenon where the induced antibody shows higher affinity to a previously encountered influenza virus strain compared with the virus strain present in the vaccine. However, we found that most of the influenza-virus-specific mAbs showed the highest affinity for the current vaccine strain. Thus, OAS does not seem to be a common occurrence in normal, healthy adults receiving influenza vaccination.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Analysis of the B cell response induced by influenza vaccination
a, PBMCs collected from 10 donors were assayed for influenza specific IgG secreting ASCs by ELISPOT assay at days 0, 7, 14, 28 and 80 days after vaccination. Each sample was measured in duplicate, averaged and plotted as ASC/106 PBMCs over time post-vaccination. b, ASCs were measured in blood by flow cytometric analysis. Shown is the frequency of the ASC gate (CD3-/CD20-/low/CD19+/CD27hi/CD38hi) for a representative donor and a summary for all ten donors normalized to total CD20+/CD19+ B cell numbers. c, HLA-DR and Intracellular expression of Ki-67 by ASCs compared to naive or memory B cells. d, The majority of ASCs at day 7 after influenza vaccination are influenza specific. Influenza and total IgG-specific ELISPOT assays from several donors were similar. e, Percentage of influenza specific memory cells per total IgG positive memory cells after mitogen stimulation as measured by ELISPOT at days 0, 7, 14, 28 and 80 days post vaccination as previously described.
Figure 2
Figure 2. The ASC response after influenza vaccination is pauci-clonal and highly diversified by somatic hypermutation
a, Comparison of the mean proportion (line) of all clonal variable region sequences from day 7 ASCs of 14 donors (points), including: the bulk RNA of 104 to 105 ASCs from 10 donors and verification by single cell RT-PCR for 4 donors (average 37 sequences per donor). The ASCs were the most clonally-related population (t-test p ≤ 0.0003). Dotted lines indicate donors from which memory and ASCs were analyzed simultaneously. Other B cell populations were from historical data analyzed in a similar fashion from our laboratory- (see Methods, Supplemental data at Nature online) b, Each point is the average frequency of somatic mutations per sequence from each donor (n values within Methods). On average the anti-influenza ASCs had accumulated more mutations than either the IgG (t-test p =0.003) or IgM (p = <0.0001) memory and GC populations. c, Indicated is the proportion of all variable genes from each B cell population with the number of somatic mutations denoted in the legend (n-values are at the center of each pie chart).
Figure 3
Figure 3. High affinity mAbs generated from single influenza specific ASCs
a, Recombinant monoclonal antibodies from day 7 IgG anti-influenza ASCs (Sup. Fig. 1b) bind to a mixture of the three influenza vaccine strain virions with high affinity. In total, 71% of the ASC antibodies bound either native antigens of influenza viruses freshly grown in eggs (62% or 53/86), or to antigens within the vaccine only (9% or 8/86, not shown). Each of the five donors were influenza specific (by donor 34, 13, 11, 15, and 21 antibodies were generated of which 45% to 85% were influenza specific). Individual antibody strain specificities are in Table 1 and Sup. Fig. 2. b, 0/86 naïve B cell antibodies bound influenza. c, Analysis by immunoprecipitation and Western blot (Sup. Fig. 3) identified the specific viral antigens bound. Hemagglutination assays were used to identify those antibodies that were inhibiting (Table 1 and Methods).
Figure 4
Figure 4. Specificity for the newly introduced influenza B strain in the vaccine suggests a minimal impact of OAS
a, Influenza B strains used for the vaccine since 1989. Throughout the Figure, strain names are color coded for the Yamagata lineage (green) and the Victoria lineage (orange/red). b, Phylogenetic tree illustrating the similarity of recent influenza B strains and the years in which each strain was included in the vaccine. The three vaccine strains tested herein (larger font) included B/Malaysia/2506/2004 (2006/7 season) that is most similar to the 2002-2004 strain (B/Hong Kong/33/2001). Conversely, the 2005/6 vaccine strain, B/Shanghai/361/2002, is more divergent. c, All anti-B strain antibodies reacted with equal or greater affinity to the current year’s vaccines when tested by ELISA.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Francis Thomas., Jr On the Doctrine of Original Antigenic Sin. Proceedings of the American Philosophical Society. 1960;104(6):572–578.
    1. Ahmed R, Oldstone MB, Palese P. Protective immunity and susceptibility to infectious diseases: lessons from the 1918 influenza pandemic. Nat Immunol. 2007;8(11):1188–1193. - PMC - PubMed
    1. Subbarao Kanta, Joseph Tomy. Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev Immunol. 2007;7(4):267–278. - PMC - PubMed
    1. Gerhard W, et al. Role of the B-cell response in recovery of mice from primary influenza virus infection. Immunol Rev. 1997;159:95–103. - PubMed
    1. Luke Thomas C., Kilbane Edward M., Jackson Jeffrey L., Hoffman Stephen L. Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment? Ann Intern Med. 2006;145(8):599–609. - PubMed

Publication types

MeSH terms